Form DEFA14A Crinetics Pharmaceutical
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Stifel Downgrades Crinetics (CRNX) to Hold
July 8, 2026 8:45 AM EDTStifel analyst Alex Thompson downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold with a price target of $85.00 (from $83.00).
The analyst comments "We are downgrading CRNX to Hold from Buy and raising our target price to $85 from $83 following the proposed acquisition by VRTX (Hold, $522.25,... More
